ThinkRadial and Merit Medical are Honored to Have Dr. Ferdinand Kiemeneij Co-Proctor this Week’s ThinkRadial™ Education

By Alicia Armeli

Today is the first day of our April ThinkRadial™ course and we couldn’t be more excited to have Guest of Honor Dr. Ferdinand Kiemeneij, MD, PhD, co-proctoring the IR and Advanced IC sections.

Recognized as the “Father of Transradial Intervention,” Dr. Kiemeneij has been at the transradial forefront for over two decades.  A patient-centric approach, transradial access is associated with fewer adverse events, shorter hospital stays, and is patient-preferred in comparison to transfemoral.1,2,3

Dr. Kiemeneij is working side-by-side with co-proctors Sandeep Nathan, MD, MSc, FACC, FSCAI, interventional cardiologist at the University of Chicago Medical Center in Chicago, Ill., and Darren Klass, MD, PhD, MRCS, FRCR, FRCPC, interventional radiologist at Vancouver General and UBC Hospitals in Vancouver, Canada.

To learn more about Think Radial training and register for future courses, talk to your Merit Representative or visit ThinkRadial.com

Alicia Armeli is a paid consultant of Merit Medical. For a complete step-by-step guide to delivery, refer to instructions for Use. Please consult product labels and inserts for any indications, contraindications, potential complications, warnings, precautions and directions for use.

REFERENCES

  1. Valgimigli, M., Gagnor, A., Calabró, P., et al. (2015). Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet, 385(9986): 2465-2476.
  2. Romagnoli, E., Biondi-Zoccai, G., Sciahbasi, A., et al. (2012). Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol, 60(24): 2481-2489.
  3. Jolly, S., Yusuf, S., Cairns, J., et al. (2011). Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet, 377(9775): 1409-1420.

Comments are closed.